These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Asymptomatic acute cytolytic hepatitis due to fluindione and associated with resistance to treatment: a case report and review of the literature]. Penot JP; Fontenelle P; Dorleac D Arch Mal Coeur Vaiss; 1998 Feb; 91(2):267-70. PubMed ID: 9749256 [TBL] [Abstract][Full Text] [Related]
3. [Hepatic and renal toxicity to fluindione (Previscan)]. Cadranel JF; Demontis R; Seddik M; Ramdani S; Belloula D; Biour M Gastroenterol Clin Biol; 2008 Oct; 32(10):816-8. PubMed ID: 18818035 [No Abstract] [Full Text] [Related]
4. Cholestatic hepatitis caused by fluindione. Stephan D; Simonnet N; Weltin D; Habersetzer F; Welsch M; Imbs JL Therapie; 2002; 57(6):589-90. PubMed ID: 12666267 [No Abstract] [Full Text] [Related]
12. [Potentiation of the anticoagulant effect of fluindione by propafenone]. Welsch M; Heitz C; Stephan D; Imbs JL Therapie; 1991; 46(3):254-5. PubMed ID: 1792662 [No Abstract] [Full Text] [Related]
13. Fluindione and drug reaction with eosinophilia and systemic symptoms: an unrecognised adverse effect? Daveluy A; Milpied B; Barbaud A; Lebrun-Vignes B; Gouraud A; Laroche ML; Ciobanu E; Bégaud B; Moore N; Miremont-Salamé G; Haramburu F; Eur J Clin Pharmacol; 2012 Jan; 68(1):101-5. PubMed ID: 21792562 [TBL] [Abstract][Full Text] [Related]
14. [Drug interaction implicating miconazole in gel form and fluindione]. Ponge T; Rapp MJ; Fruneau P; Ponge A; Wassen-Hove L; Larousse C; Cottin S Therapie; 1987; 42(4):412-3. PubMed ID: 3686478 [No Abstract] [Full Text] [Related]